remains unknown. In this study we have focused on the molecular consequences of the 23 polymorphism on the regulation of MUC5B expression. We have identified a combined 24 mechanism involving both methylation and direct transcriptional regulation mediated 25 by the polymorphic variant on MUC5B overexpression. Our results demonstrate that the 26 minor allele (T) associated with rs35705950 disturbs a DNA methylation site, directly 27 increasing MUC5B expression. Furthermore, this same variant also creates a novel 28 binding site for the transcription factor C/EBPβ leading to transcriptional activation of 29 MUC5B. Our findings provide a novel insight into the regulatory effects of the IPF risk Introduction 37 Idiopathic pulmonary fibrosis (IPF) is an irreversible interstitial lung disease 38 characterized by a progressive scarring of lung parenchyma often leading to a fatally 39 declining lung function. IPF incidence has been estimated to be around 75/100,000, 40 affecting 5 million people world-wide [1] [2] [3] . Furthermore, IPF is believed to be an under 41 diagnosed disease [4] [5] [6] . 42 Due to the complexity and progressive nature of the disease, available treatments are 43 limited and have only a modest impact on IPF progression. Until recently, only lung 44 transplant has been proved to increase survival [1] . In recent years, improvement in 45 development of new therapies has met some success, as two novel drugs have been 46 introduced, pirfenidone and nintedanib. Both drugs are believed to target profibrotic 47 signalling pathways in IPF. Pirfenidone inhibits TGF-β1 production possibly by inhibiting 48 the upregulation of HSP47 and Col1 RNA in fibroblasts [7] . Nintedanib is a potent small-49 molecule receptor tyrosine kinase inhibitor targeting platelet-derived growth factor 50 receptors (PDGF-R), fibroblast growth factor receptors (FGFR) and vascular endothelial 51 growth factor (VEGF) -family tyrosine kinase receptors [8] . 52 Both genetic and environmental factors are believed to contribute to the onset and 53 progression of the disease. Several environmental factors have been associated with IPF, 54 including exposure to metal and wood dust [9] [10] [11] [12] , viruses [13] [14] [15] , drugs [16] [17] [18] , and 55 cigarette smoke [19] [20] [21] . Recent findings point to genetic factors as major triggers of IPF. 56 Rare mutations found in 6 genes (TERT [22, 23] , TERC [22, 23] , RTEL1 [24, 25] , PARN [25] , 57 STPC [26, 27] and SFTPA2 [28]), with associated variants in 11 different loci [29] indicate 58 The MUC5B promoter variant rs35705950 is the strongest known risk factor (genetic and 81 otherwise) for the development of IPF [32, 33] . This variant is unusual as it is relatively 82 simple, with no other variants in strong linkage disequilibrium and carries a strong eQTL 83 association with MUC5B expression in lung. The odds ratio (OR) associated with carrying 84 one allele of the variant is 4.5-6.6, while homozygosity leads to an OR of 9. 6-20.2 [30, 85 31, 37-41] . Furthermore, carriers of the MUC5B variant are also at risk of getting 86 subclinical interstitial lung disease based on screening with high-resolution CT [4] . 87 Interestingly, recent studies have examined the relevance of MUC5B variation in other 88 ethnic groups, showing that the frequency of rs35705950 minor allele (a G-to-T SNP) is 89 11, 8 and 1% among European, South Asian and East Asian populations, respectively [38, 90 42, 43] , and it is almost non-existent in Africans [44] . Despite the different prevalence, 91 the evidence indicates that the risk of developing IPF associated with the variant is 92 comparable to the risk observed in European population [4, 31] Even though the MUC5B variant has a strong and consistent genetic association with IPF 107 and the variant seems to positively regulate MUC5B expression, the mechanism 108 underlying its role in IPF is poorly understood. It has been hypothesized that, due to the 109 large size of the MUC5B protein, its production may carry a significant metabolic stress, 110 which can interfere with differentiation of airway stem cells [33] . It should also be 111 emphasized that due to the increased expression level there could also be secondary 112 problems with post-translational modifications, such as glycosylation. In a mouse model 113 of intestinal inflammation aberrant mucin assembly has been shown to cause ER-stress 114 through activation of the unfolded protein response leading to inflammation, apoptosis, 115 and wound repair [48] . ER-stress has been shown to be involved in IPF, specifically in 116 cases caused by mutations in surfactant proteins, another protein that is highly 117 glycosylated [49] . Other proposed mechanisms consider the possibility that IPF is a 118 mucociliary disease caused by recurrent injury/inflammation/repair at the 119 bronchoalveolar junction, as MUC5B overexpression might cause a reduction in 120 mucociliary function and retention of particles leading to lung injury [33] . 121 In this study, we aim to define the molecular mechanisms involved in mediating the 122 effects of the MUC5B variant (T allele) on MUC5B expression. We use two immortalized 123 human bronchial epithelial cell lines (BCi_NS1.1 and VA-10) and the well-established 124 adenocarcinoma cell line A549 to corroborate the positive effects of the variant on 125 MUC5B expression. With our models, we show that the T allele is associated with a 126 twofold mechanism affecting MUC5B expression, leading to both the disruption of a 127 DNA methylation site that directly increases MUC5B expression and the creation of a 128 novel C/EBPβ transcription factor binding site that also positively regulates MUC5B 129 expression.
130

Material and methods
131
Allele-specific match for DNA binding proteins 132 Motifs for DNA binding proteins were retrived through MotifDB, a bioconductor package 133 for R, wherein we made use of the Catalog of Inferred Sequence Binding Preferences 134 (CIS-BP) database containing information on sequence specificities for 313 human DNA 135 binding proteins [50] . We then used matchPWM implemented in Biostrings for R to 136 calculate PWM (position weight matrix) scores for DNA sequences with and without the 137 rs35705950 minor allele. P-values were assessed by scoring each of the 313 CIS-BP 138 motifs on 100 thousand DNA sequences randomly selected from regulatory regions in 139 the human genome (ChromHMM 25-state regions assigned as promoter, tss, or 140 enhancer). We then calculate two P-values for each motif as the area under the null-141 curve above the observed score for the corresponding motif match against the minor 142 and major alleles, respectively. P-values less than 0.01 were then considered as 143 ´candidate binding sites´ and, as an indicator of biological relevance, we considered only 144 sites wherein the rs35705950 minor allele alters an important nucleotide in the 145 matching of the motifs to the DNA sequence defined here as nucleotides accounting for 146 a mininum of 0.70 (or 70%) at a given position in the probability position matrices. The cultures were maintained on chemically defined bronchial epithelial cell medium 166 (BEGM, Cell Applications, San Diego) for 5 days, 0,5 ml in the upper chamber and 1.5 ml 167 in the lower chamber. After 5 days, medium was changed to DMEM/F-12 (Invitrogen), 168 supplemented with 2% UltroserG (Cergy-Saint-Christophe, France) for additional 5 days. 169 For ALI culture, the medium was aspired from the apical side and the cell layer rinsed 1x 170 with PBS. 171 Goblet cell differentiation by IL-13 treatment 172 Cells were cultured for 5 days on BEGM and then for 5 days on DMEM/UG in a 173 submerged culture. After 5 days of ALI culture, IL-13 (Peprotech, London, UK) was added 174 to the basal side to a final concentration of 25 ng/ml and cultured for 14 days.
175
Immunofluorescence staining 176 Cells were rinsed twice with chilled PBS. The fixation of cells was performed using 100% 177 methanol at -20°C overnight. Subsequently, cells were submerged in 100% acetone for 178 one minute. Staining was performed using immunofluorescence buffer, (IMF) (0.1% TX-179 100, 0.15M NaCL, 5nM EDTA, 20mM HEPRES, pH 7.5, 0.02% NaN3 as preservative). Cells 180 were incubated with primary antibody overnight at +4°C, and then rinsed three times 181 for 15 min with IMF buffer. Cells were then incubated with a secondary antibody and 182 DAPI for two hours at room temperature, followed by four times washing with IMF 183 buffer. Cells were mounted using ProLong Antifade (Thermo Fisher Scientific). 184 Antibodies used for these experiments are listed in S1 Table. 185 195 Antibodies used for these assays are listed in S1 Table. Immunofluorescence Table. 206 207 To produce lentiviral cell lines containing pGreenFire1™ Pathway Reporter lentivector 208 (Cat#TR010PA-N and Cat#TR000PA-1, System Bioscience) expressing the MUC5B 209 promoter region and controls, we followed the general guideline provided by System 210 Bioscience. Briefly, 70% confluent HEK-293T cells were cultured for 24 h w/o antibiotics 211 and transfected (Lipofectamine, Thermo Fisher Scientific) with lentiviral transfection 212 constructs and packaging plasmids (psPAX2 and pMD2.G) (Addgene plasmids #12260 213 and #12259, respectively). Culture medium containing the virus was harvested 24 and 214 48 hours post transfection and centrifuged at 1250 rpm at 4°C for 5 minutes and filtered 215 through 0,45 µm filter. Lentiviral particle solution was added to culture medium 216 (containing 8 µg/ml polybrene) and then added to culture flasks of 70% confluent cells 217 (BCi_NS1.1, VA10 and A549) at a low multiplicity of infection (MOI) and incubated for 218 20 hours. Cells were then cultured further for 24 hours in fresh culture media. Infected 219 cells were then selected with puromycin or neomycin as appropriate for 48hs. Plasmids 220 used for this experiment are listed in S2 Table. 221
DAB staining
Production of lentiviral and cell transduction
Luciferase Assay
222
Each cell type was seeded at 70% confluence one day before transfection in a 96 well 223 plate. To perform the luciferase assay, the Dual-Glo® Luciferase Assay System kit 224 supplied by Promega was used, following the general guidelines provided with the kit. 225 Luminosity was measured in a microplate reader Modulus TM II (Turner BioSystem). 226 Luciferase measurement was normalized using Renilla co-transfection. Plasmids used 227 for this experiment are listed in S2 Table. 228 Real Time qPCR 229 RNA was isolated using Tri-Reagent® solution (Ambion) and cDNA preparation was 230 carried out using RevertAid™ First strand cDNA Synthesis Kit (Fermentas) according to 231 the manufacturer's instructions. Real-time PCR using Power SYBR Green PCR Master mix 232 (Applied Biosystems) was used to detect the relative quantity of each cDNA. GAPDH was 233 used as the endogenous reference gene. Data were analysed using 7500 Software v2.0 234 (Applied Biosystems). All primers used are listed in S3 Table. 235 Table. 267 
Western Blot
5-aza-2'-deoxycytidine DNA Methylation Inhibition
Results
307
Rs35705950 risk allele for IPF is associated with higher expression of MUC5B. 308 The common polymorphism rs35705950, where a G is replaced by a T nucleotide, has 309 been shown in two GWAS studies to be correlated with a predisposition to develop IPF 310 [30, 31] . The polymorphism is located in a mucin gene cluster, three kilobases upstream 311 of the transcription start site of MUC5B on chromosome 11 (S1 Fig) . The molecular 312 mechanism explaining how this polymorphism affects the aetiology of IPF has not been 313 elucidated, although both hetero-and homozygote carriers have been shown to express 314 higher levels of MUC5B in the lung epithelium (S1 Fig, S2 Fig) (Fig 1c) , showing a direct effect of the T allele on MUC5B expression. 333 The above data support the previous findings [55] that the T allele confers an increased 334 promoter/enhancer activity to the MUC5B upstream cis-regulatory sequence.
335
The rs35705950 T allele disrupts a repressive CpG DNA methylation site 336 It has been previously reported that the methylation of several CpG islands in the 4.1kb 337 promoter region of MUC5B affects the expression of the MUC5B protein [47] . 338 Interestingly, the presence of the T allele disrupts a CpG site that was previously 339 characterized as methylated in the wild type. We hypothesized that the effects of the T 340 allele could be mediated, at least in part, through epigenetic regulation. To analyse the 341 effect of DNA methylation on MUC5B expression we used an air-liquid interphase (ALI) 342 culture of BCi_NS1.1 cells. Under these conditions the cells differentiate into both, 343 goblet cells producing mucins and ciliated cells [56] . We treated these cultures with 344 5'aza2'-deoxycytidine (5'AZA2'), a DNA methylation inhibitor. 5'AZA2' treatment 345 resulted in increased expression of MUC5B and MUC5AC indicating that DNA 346 methylation either directly or indirectly impacts MUC5B expression (Fig 2a) . To directly 347 address the potential effects of DNA-methylation at the T allele, we used M.SssI CpG 348 methyltransferase to in vitro methylate the 4.1 kb MUC5B promoter region. The 349 promoter (with T allele or WT) was restriction cut from the plasmid, and the fragments 350 was in vitro methylated using M.SssI CpG methyltransferase prior to ligating back into a 351 luciferase reporter plasmid and transiently transfected into the three cell lines. We 352 compared the effects of the mutation with (Fig 2b, bottom) or without (Fig 2b, top) 353 direct in vitro methylation. In Fig 2b without in vitro methylation no difference is seen in 354 luciferase activity in VA10 or A549 cells between T allele and WT while after in vitro 355 methylation a significant increase is seen in the T allele carrying the luciferase plasmid 356 compared to WT in all three cell lines. This supports the idea that differential CpG 357 methylation of the T allele and wild type allele is at least partially involved in regulating 358 MUC5B expression. 359 Targeted bisulfite sequencing of the region in our cell lines further revealed that 360 methylation was present in all cell lines at the WT genotype although the BCi_NS1.1 cells 361 is less methylated (21-40%), than in both VA10 and A549 cells (81-100%) under normal 362 cell culture conditions (Fig 2d) . All the cell lines are WT (G allele) homozygous carriers at 363 the rs35705950 site, as stated above. The CRISPR/Cas9 edited A549 cell lines harbouring 364 the heterozygous [G/T] genotype showed less methylation (41-60%, clones 1-2, 21-40% 365 clone 3) at the risk allele (Fig 2e) compared to A549 WT (81-100%), confirming that the 366 presence of the T allele reduces methylation in the polymorphic site. This suggests that 367 direct DNA methylation might at least partially explain the increased MUC5B expression 368 in individuals carrying IPF risk associated T allele. 369 C/EBPβ mediates MUC5B overexpression through rs35705950 T allele. 370 Even though our data support a role of differential DNA methylation to explain the 371 effects of T allele on MUC5B expression, additional mechanisms might also be at play. 372 To further study the potential effects of the T allele of rs35705950 we used Match, a 373 weight matrix-based program for predicting transcription factor binding sites in DNA 374 sequences using the DNA sequence flanking rs35705950 polymorphism. The program 375 uses a library of positional weight matrices from TRANSFAC® Public 6.0. Fig 3a shows 376 the predicted transcription factor binding motif. Binding motifs for PAX2 and PAX4 377 overlap the polymorphism in the WT sequence while the T allele leads to the loss of the 378 PAX4 motif. The T allele furthermore leads to a gain of a novel CCAAT/enhancer-binding 379 proteins (C/EBPs) motif (Fig 3a, S6a,S6b Fig, S3 Table) . Due to the low expression levels Immunofluorescence staining on four IPF lung samples show that C/EBPβ and MUC5B 397 are co-expressed in airway epithelial cells (Fig 3b, S3 Fig) . Furthermore, in healthy lung 398 samples C/EBPβ is highly expressed in alveolar cells resembling alveolar macrophages 399 and they also express high levels of MUC5B (S3 Fig) . 400 In addition to the aforementioned co-expression, C/EBPβ might act through a common 401 signalling pathway potentially driving MUC5B overexpression through the T allele. IL-13 402 has been previously used to induce goblet cell hyperplasia in asthma models and has 403 also been used to induce MUC5AC expression in cell culture models [56] . We cultured 404 both VA10 and BCi_NS1.1 cell lines, under ALI culture conditions with or without IL-13. 405 In both cell lines, IL-13 induced C/EBPβ as well as MUC5B expression at both the protein 406 (Fig 3c) and mRNA level (Fig 3d) , suggesting a co-regulatory pathway. 407 To analyse specifically the differential effects of C/EBPβ on MUC5B cis-regulatory 408 domain on the wild type and T alleles, we overexpressed the C/EBPβ isoforms in the 409 BCi_NS1.1 (Fig 4a) , A549 (Fig 4b) and VA10 (Fig 4 a, b ). When both isoforms were co-expressed in equimolar concentrations 416 an increased luciferase signal was seen in the BCi_NS1.1 cell line. 417 To further corroborate the role of C/EBPβ in regulating MUC5B expression through the 418 risk allele, we knocked down C/EBPβ expression using siRNAs targeting either the 419 LAP/LAP* or all isoforms. Stable cell lines carrying the luciferase reporter vector and 420 A549 CRISPR clones were used to analyse the effect of C/EBPβ knock-down on MUC5B 421 20 expression by RT-qPCR (Fig 4c, S6e Fig) and luciferase reporter assay (Fig 4d, S6f Fig) . 422 Our results show that siRNAs targeting C/EBPβ lowers MUC5B expression in T allele 423 genotype to a similar level as wild type. 424 The correlation between C/EBPβ expression and the strong T allele specific positive 425 expression suggests that this transcription factor is a candidate key regulator of MUC5B 426 expression in carriers of the T allele in IPF. The results presented in this study suggest that the IPF associated polymorphism, 430 rs35705950 (T allele), has a direct and major effect on MUC5B expression. We have 431 shown that it is mediated through a combination of effects on both epigenetic and 432 transcriptional regulatory mechanisms. Specifically, we have shown that the T allele 433 directly reduces DNA methylation and that this increases the MUC5B expression in our 434 cell culture models. Furthermore, we have shown that the T allele creates a novel 435 C/EBPβ binding site that strongly positively regulates MUC5B expression. 436 CpG DNA methylation has previously been identified as an important regulatory 437 mechanism for mucins. The human genes MUC2, MUC5AC, MUC5B and MUC6 are 438 clustered on chromosome 11p15 and their promoters show a GC-rich structure [47] . 439 Hypermethylation of MUC5B promoter is the major mechanism responsible for its 440 silencing, combined with histone acetylation while the expression of MUC5AC was rarely 441 influenced by epigenetic marks. In this study, we confirm a general role of methylation 442 in MUC5B repression. Furthermore, we show that the rs35705950 T allele disrupts a CpG 443 methylation site and this disruption relieves a DNA methylation-dependent negative 444 regulation site. Furthermore, the in vitro methylation assay corroborates the differential 445 methylation pattern between alleles. 446 Data from the ENCODE project suggest that the area surrounding the MUC5B 447 polymorphism is located within a cis-regulatory element, based on both, the DNAse 448 hypersensitivity cluster and the high number of transcription factors binding in the area. 449 Our data, based on in silico binding analysis, predicts a C/EBPβ binding site overlapping 450 rs35705950 when the IPF associated T allele is present. Here, we directly show that Other tissues that express high levels of MUC5B, such as salivary glands, stomach, small 484 and large intestine are not shown to have a positive eQTL with the polymorphic site. 485 In our results, we have also shown that C/EBPβ is co-expressed with MUC5B. Its 486 presence is predominantly in basal cells in the pseudostratified epithelium under normal 487 conditions, while in fibrotic lungs, it is also expressed in ciliated and goblet cells. This 488 could be related with the role of C/EBPβ previously associated with fibrosis development 489 [74, 75] . 490 To summarize, we have shown that T allele associated with the rs35705950 491 polymorphism strongly induces MUC5B overexpression. Interestingly, this appears to be 492 through two independent mechanisms. Firstly, it leads to disruption of a CpG 493 methylation site that naturally represses MUC5B, resulting in an overexpression. Central PMCID: PMCPMC4936814. 551 while the inhibitory isoform (LIP) inhibits the differential activity between WT and T 860 allele. c) siRNA silencing C/EBPβ isoforms, LAP and LIP together or C/EBPβ LAP alone, 861 was performed on A549 CRISPR Clone 1 compared to A549 Cas9 Control cell line. Inhibition 862 of C/EBPβ restores differential MUC5B expression driven by the T allele to the WT 863 associated MUC5B expression levels while no effect is seen in A549 Cas9 Control cell line. 
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